, is a British immunologist
(born 27 February 1945
). He worked in the Department of Pathology, University of Cambridge
, from 1973, becoming head of the Immunology Division in 1989. He was made a Fellow of the Royal Society
in 1990. In 1994, he took up the position of head of the Sir William Dunn School of Pathology at the University of Oxford
Waldmann is best known for his work on therapeutic monoclonal antibodies, particularly Campath-1, now licensed as alemtuzumab for the treatment of chronic lymphocytic leukemia.